Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross SD Voydeya Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.05.48

    Voydeya (danicopan) coverage for paroxysmal nocturnal hemoglobinuria

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.05.48 alerts

    Get alerted when Policy 05.05.48 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity requirements for Voydeya (danicopan) used as add-on therapy to ravulizumab or eculizumab for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. Coverage applies when the documented clinical, laboratory, prescriber, concomitant-therapy, and dosing requirements are met.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyVoydeya (danicopan) coverage for paroxysmal nocturnal hemoglobinuria
    Policy CodePolicy 05.05.48
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing adult PNH, flow-cytometry-confirmed GPI-AP deficiency, clinically significant extravascular hemolysis, and the required laboratory thresholds.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial authorization period
    12 monthsContinuation authorization period
    ≤ 9.5 g/dLHemoglobin threshold
    ≥ 120 × 10⁹/L

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Reticulocyte count threshold
    4 cards/28 daysQuantity limit
    HematologistPrescriber requirement

    Coverage Criteria

    Initial Therapy Criteria

    Authorization of 6 months may be granted when all of the following criteria are met.

    Initial therapy criteria

    • Age and diagnosis

      • Age: The patient is at least 18 years of age.≥ 18 years
      • PNH diagnosis: The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) is confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs).Examples include at least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells

        Flow cytometry must be used to demonstrate GPI-AP deficiency.

    • Clinically significant extravascular hemolysis

      • Hemoglobin: The patient has hemoglobin less than or equal to 9.5 g/dL while receiving Ultomiris (ravulizumab) or eculizumab.≤ 9.5 g/dL
      • Absolute reticulocyte count: The patient has an absolute reticulocyte count greater than or equal to 120 × 10⁹/L while receiving Ultomiris (ravulizumab) or eculizumab.≥ 120 × 10⁹/L
    • Treatment requirements

      • Prior therapy: The patient has been receiving treatment with Ultomiris (ravulizumab) or eculizumab for at least 6 months.At least 6 months
      • Concomitant therapy: The requested medication will be used concomitantly with Ultomiris (ravulizumab) or eculizumab.
      • Prohibited concomitant therapy: The requested medication will not be used concomitantly with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).

    Continuation Therapy Criteria

    Authorization of 12 months may be granted for continued treatment when all of the following criteria are met.

    Continuation therapy criteria

    • Safety and disease status: There is no evidence of unacceptable toxicity or disease progression while the patient is on the current regimen.
    • Clinical response: The patient demonstrates a positive response to therapy.

      Examples include improvement in hemoglobin levels or normalization of lactate dehydrogenase (LDH) levels.

    • Concomitant therapy: The requested medication will be used concomitantly with Ultomiris (ravulizumab) or eculizumab.
    • Prohibited concomitant therapy: The requested medication will not be used concomitantly with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).

    Voydeya (danicopan) must not be used as monotherapy. It is intended only as add-on therapy to ravulizumab or eculizumab.

    Voydeya must not be used concomitantly with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).

    Voydeya (danicopan) is considered not medically necessary for members who do not meet the coverage criteria established in this policy.

    Clinical Coding Requirements

    Minimum age requirement
    Minimum ageAt least 18 years
    Covered populationAdults with paroxysmal nocturnal hemoglobinuria
    Treatment contextTreatment of extravascular hemolysis
    PNH cell population requirement
    PNH cell populationAt least 5% PNH cells
    Diagnostic purposeConfirmation of paroxysmal nocturnal hemoglobinuria
    Detection methodGPI-AP deficiency demonstrated by flow cytometry

    Authorization and Documentation Actions

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial treatment. Authorization for 6 months may be granted for adults with PNH and clinically significant extravascular hemolysis when all clinical requirements are satisfied and the required documentation is submitted.

    • Patient is at least 18 years of age.
    • PNH is confirmed by deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs), such as at least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells.
    • Flow cytometry demonstrates GPI-AP deficiency.
    • Clinically significant extravascular hemolysis is present while receiving Ultomiris (ravulizumab) or eculizumab, with hemoglobin <= 9.5 g/dL and absolute reticulocyte count >= 120 x 10^9/L.
    • The patient has received Ultomiris (ravulizumab) or eculizumab for at least 6 months.
    • Voydeya will be used concomitantly with Ultomiris (ravulizumab) or eculizumab and not with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).
    Prior Authorization

    Paroxysmal Nocturnal Hemoglobinuria Background

    Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder involving deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs), which can be demonstrated by flow cytometry. In adults with PNH, Voydeya is used as add-on therapy to ravulizumab or eculizumab for extravascular hemolysis.

    Policy Definitions

    Extravascular hemolysis and add-on therapy
    Extravascular hemolysisExtravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria
    Voydeya useVoydeya (danicopan) is used as add-on therapy to ravulizumab or eculizumab
    Monotherapy limitationVoydeya should not be used as monotherapy
    GPI-AP deficiency
    GPI-AP deficiencyDeficiency of glycosylphosphatidylinositol-anchored proteins
    Confirmation methodDemonstrated by flow cytometry
    Example findings

    Initial PNH Approval Criteria

    PNH Initial Approval Criteria

    Authorization of 6 months may be granted for treatment of extravascular hemolysis in patients with PNH when all of the following criteria are met.

    PNH initial approval criteria

    • Age and diagnosis

      • Age: The patient is at least 18 years of age.≥ 18 years
      • PNH diagnosis: The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) is confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs).Examples include at least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells

        Flow cytometry must be used to demonstrate GPI-AP deficiency.

    Continuation PNH Criteria

    PNH Continuation Criteria

    Authorization of 12 months may be granted for continued treatment when all of the following criteria are met.

    PNH continuation criteria

    • Safety and disease status: There is no evidence of unacceptable toxicity or disease progression while the patient is on the current regimen.
    • Clinical response: The patient demonstrates a positive response to therapy.

      Examples include improvement in hemoglobin levels or normalization of lactate dehydrogenase (LDH) levels.

    • Concomitant therapy: The requested medication will be used concomitantly with Ultomiris (ravulizumab) or eculizumab.

    Voydeya Quantity Limit

    Standard quantity limit
    MedicationVoydeya (danicopan)
    Standard quantity limit4 blister cards per 28 days
    Quantity period28 days
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyVoydeya (danicopan) coverage for paroxysmal nocturnal hemoglobinuria
    Policy CodePolicy 05.05.48
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing adult PNH, flow-cytometry-confirmed GPI-AP deficiency, clinically significant extravascular hemolysis, and the required laboratory thresholds.
    SourceLink
    On This Page
    Coverage CriteriaClinical Coding RequirementsAuthorization and Documentation ActionsParoxysmal Nocturnal Hemoglobinuria BackgroundPolicy DefinitionsInitial PNH Approval CriteriaContinuation PNH CriteriaVoydeya Quantity Limit
    GPI-AP-deficient polymorphonuclear cell requirement
    GPI-AP-deficient polymorphonuclear cellsAt least 51%
    Diagnostic purposeConfirmation of GPI-AP deficiency in paroxysmal nocturnal hemoglobinuria
    Detection methodFlow cytometry
    Hemoglobin threshold
    Hemoglobin thresholdNo greater than 9.5 g/dL
    Clinical findingClinically significant extravascular hemolysis
    Required laboratory findingsMust be accompanied by an absolute reticulocyte count of at least 120 × 10⁹/L
    Absolute reticulocyte count threshold
    Absolute reticulocyte countAt least 120 × 10⁹/L
    Clinical findingClinically significant extravascular hemolysis
    Required laboratory findingsMust be accompanied by hemoglobin no greater than 9.5 g/dL
    Prior ravulizumab or eculizumab therapy
    Prior therapy durationAt least 6 months
    Qualifying therapiesRavulizumab (Ultomiris) or eculizumab
    Current treatment requirementVoydeya must be used concomitantly with ravulizumab or eculizumab

    Continuation Prior Authorization Required

    Reauthorization is required for continued treatment. Authorization for 12 months may be granted when the patient remains on the required concomitant regimen, has a positive response, and has no unacceptable toxicity or disease progression.

    • Submit chart notes or medical records supporting positive clinical response.
    • Document no evidence of unacceptable toxicity or disease progression on the current regimen.
    • Document positive response to therapy, such as improved hemoglobin levels or normalized lactate dehydrogenase (LDH) levels.
    • Voydeya must continue to be used concomitantly with Ultomiris (ravulizumab) or eculizumab.
    • Voydeya must not be used concomitantly with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).
    Documentation Required

    Initial Clinical Documentation

    Submit the required initial clinical documentation with the prior authorization request. The records must establish GPI-AP deficiency and clinically significant extravascular hemolysis.

    • Flow cytometry results demonstrating deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs).
    • Hemoglobin result demonstrating hemoglobin <= 9.5 g/dL.
    • Absolute reticulocyte count demonstrating a count >= 120 x 10^9/L.
    • Related clinical records supporting clinically significant extravascular hemolysis while the patient is receiving Ultomiris (ravulizumab) or eculizumab.
    Documentation Required

    Continuation Clinical Documentation

    Submit continuation clinical documentation with the reauthorization request. Chart notes or medical records must support that the patient is responding positively to therapy and remains appropriate for ongoing treatment.

    • Document improvement in hemoglobin levels, normalization of LDH levels, or another positive clinical response.
    • Document no unacceptable toxicity or disease progression while on the current regimen.
    Denial Risk

    Improper Concomitant Therapy May Result in Denial

    Voydeya must not be used as monotherapy or with prohibited complement therapies. It should be prescribed only as an add-on to Ultomiris (ravulizumab) or eculizumab.

    • Do not use Voydeya as monotherapy; it has not been shown to be effective as monotherapy.
    • The regimen must include concomitant Ultomiris (ravulizumab) or eculizumab.
    • Do not use Voydeya concomitantly with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).
    Denial Risk

    Criteria Not Met: Not Medically Necessary

    Requests may be denied when the applicable initial or continuation criteria are not met. Voydeya is considered not medically necessary for members who do not satisfy the policy requirements.

    • Initial requests must meet all age, confirmed PNH, flow cytometry, hemolysis, prior Ultomiris or eculizumab treatment, concomitant-therapy, and prohibited-therapy requirements.
    • Continuation requests must demonstrate positive response, no unacceptable toxicity or disease progression, and compliance with the required concomitant-therapy requirements.
    • Missing required documentation or failure to meet any applicable criterion may result in denial.
    Note

    Hematologist Requirement

    The requested medication must be prescribed by or in consultation with a hematologist. Include the prescriber specialty or hematology consultation in the submitted records.

    • Prescribing hematologist documentation is acceptable.
    • If the prescriber is not a hematologist, submit documentation of consultation with a hematologist.
    At least 5% PNH cells or at least 51% GPI-AP-deficient polymorphonuclear cells
  1. Clinically significant extravascular hemolysis

    • Hemoglobin: The patient has hemoglobin less than or equal to 9.5 g/dL while receiving Ultomiris (ravulizumab) or eculizumab.≤ 9.5 g/dL
    • Absolute reticulocyte count: The patient has an absolute reticulocyte count greater than or equal to 120 × 10⁹/L while receiving Ultomiris (ravulizumab) or eculizumab.≥ 120 × 10⁹/L
  2. Treatment requirements

    • Prior therapy: The patient has been receiving treatment with Ultomiris (ravulizumab) or eculizumab for at least 6 months.At least 6 months
    • Concomitant therapy: The requested medication will be used concomitantly with Ultomiris (ravulizumab) or eculizumab.
    • Prohibited concomitant therapy: The requested medication will not be used concomitantly with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).
  3. Prohibited concomitant therapy: The requested medication will not be used concomitantly with Empaveli (pegcetacoplan) or Fabhalta (iptacopan).